Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23130561 | 0.90 | HTR6 (0.38) | HTR6HTR2AHTR2CKMT2AMEN1 | |
| SCHEMBL28606804 | 0.86 | KMT2A (0.38) | HTR6HTR2AKMT2AMEN1L3MBTL1 | |
| SCHEMBL21963548 | 0.85 | KDM4E (0.39) | HTR6KDM4EUBE2NL3MBTL1PKM | |
| SCHEMBL21068128 | 0.84 | JAK2 (0.46) | HTR6KDM4EUBE2NL3MBTL1POLB | |
| SCHEMBL21058468 | 0.83 | HTR6 (0.39) | HTR6KDM4EUBE2NL3MBTL1PKM | |
| SCHEMBL12011379 | 0.82 | HTR6 (0.45) | HTR6KMT2AMEN1KDM4EUBE2N | |
| SCHEMBL16968327 | 0.81 | KDM4E (0.37) | HTR6KMT2AMEN1KDM4EUBE2N | |
| SCHEMBL28606806 | 0.80 | NPC1 (0.39) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL29414046 | 0.79 | KDM4E (0.56) | HTR6KDM4EUBE2NL3MBTL1POLB | |
| SCHEMBL10182014 | 0.79 | KDM4E (0.56) | HTR6KDM4EUBE2NL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| EP-4253375-B1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-12473272-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| EP-3880671-B1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO N CORP (KR) | 2025-03-12 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | HK INNO.N CORPORATION (KR) | 2024-12-31 | — | — | US | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
| WO-2017050938-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | HTR6 3016/4885HTR2A 3313/4885HTR2C 1714/4885 |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | HTR6 3016/4885HTR2A 3313/4885HTR2C 1714/4885 |
| US-12473272-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | HTR6 1875/4885HTR2A 2282/4885HTR2C 2139/4885 |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | HTR6 2304/4885HTR2A 3008/4885HTR2C 1252/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | HTR6 1397/4885HTR2A 3189/4885HTR2C 1934/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | HTR6 2312/4885HTR2A 2687/4885HTR2C 3501/4885 |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | MAP3K20, MAP3K1, MAP3K15 | HTR6 4253/4885HTR2A 4184/4885HTR2C 3848/4885 |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | HTR6 3016/4885HTR2A 3313/4885HTR2C 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.